Principal Investigator Profile

Dr. Séan Dinneen

Biography

Dr Seán Dinneen received his medical degree from University College Cork Medical School. He undertook postgraduate training in medicine in Ireland and then went to the United States where he trained in Diabetes and Endocrinology at the Mayo Clinic. After a period on staff at the Mayo Clinic he was appointed as a Community Diabetologist in Addenbrooke’s Hospital, Cambridge. He spent 5 years working in the NHS before returning to Ireland in 2005 to take up a Senior Lecturer post in Medicine in Galway University Hospitals. His professional interests are in delivering programmes of self-management education for people with diabetes and developing optimal models of community-based diabetes care.

Research Areas:

Developing optimal models for community-based diabetes care: this has been a major focus of Dr Dinneen’s work both at the Mayo Clinic and in Addenbrooke’s. Dr Dinneen, with the help of Sue Holmes, a GP with a special interest in diabetes, have produced a robust (and continuously updated) set of diabetes clinical practice guidelines for Southern Cambridgeshire. Using community-based diabetes specialist nurses they have introduced a number of different approaches to community-based care in the locality.

The role of Information Technology in Diabetes Care: to properly integrate care between the hospital and the community requires knowledge of the entire population of people with diabetes and the ability to share information easily across interfaces. Dr Dinneen was involved in the implementation of a clinical information system in Addenbrooke’s was awarded 3 ^rd place (and £10,000) in the Trust’s 2003/4 Outstanding Achievement Awards.

Self-management education programmes for people with diabetes: Dr Dinneen’s involvement with the Dose Adjustment for Normal Eating (DAFNE) programme has been the most professionally rewarding work of his career. The principles of Therapeutic Patient Education, expounded originally by Jean-Phillipe Assal remain a professional mantra for him. Dr Dinneen was involved in the implementation of DAFNE in Addenbrooke’s and was recognised in a 2002/3 Outstanding Achievement Award. He is currently involved in the implementation and evaluation of the Irish DAFNE Study and a new model of ongoing care for people with type 1 diabetes, http://www.controlled-trials.com/ISRCTN79759174. Dr Dinneen is also a member of the Expert Advisory Group for Diabetes of the Health Service Executive. This is a 20 member group convened by the CEO to advise on all aspects of diabetes care delivery in Ireland. He is a member of the Standards of Care, Rethinopathy and Education/ Patient Empowerment sub-groups.

Leadership and Teamwork: these are key components of good diabetes care. Dr Dinneen has been fortunate to work with and to lead a number of very effective teams. The Addenbrooke’s Foot Team and the Southern Cambridgeshire Community Diabetes Team were both acknowledged by Addenbrooke’s Hospital and given “Over and Above” awards in 2004.

Current Projects:

• Principal Investigator on “The West of Ireland Diabetes Foot Study: Epidemiology, cost, feasibility and implications for clinical practice and policy”. Funded by the Diabetes Federation of Ireland and Medical Research Charities Group in conjunction with the Health Research Board; €217,571 over 3 years.
• Co-Investigator on “Patient Monitoring and Feedback Mechanism for Neuropathic Feet”. PI is Dr Martin Glavin, Department of Electronic Engineering, NUI, Galway. Funded by Enterprise Ireland Commercialisation Fund Proof of Concept Phase 2007
• Co-Investigator for “Towards a national diabetes register for Ireland: theory, practice and policy”, PI is Prof Colin Bradley, Department of General Practice, UCC. Funded by the Health Research Board’s Health Services R&D Awards 2006. Total award €932,480; NUI, Galway allocation €96,483 over 4 years.
• Principal Investigator on “Implementing and evaluating a structured education programme and a new model of ongoing care for Type 1 diabetes: the Irish DAFNE Study”. Funded in March 2005 by the Health Research Board’s Health Services R&D Awards; 1.2 million Euro over 5 years
• Co-Investigator on “Use of a diabetes electronic management system (DIAMOND) to support a shared care diabetes programme in Galway”. Funded in 2005 by the Health Research Board Infrastructure Grant.
• Translation of Optimal Diabetes Care: from research to practice. This study is funded as part of a strategic alliance between the Division of Endocrinology, Mayo Clinic and Novo Nordisk Pharamaceuticals, Copenhagen, Denmark.

Peer Review Articles:

Glynn LG, Buckley B, Reddan R, Newell J, Hinde J, Dinneen SF, Murphy AW.  Multimorbidity and risk among patients with established cardiovascular disease: a cohort study. BJGP 2008:58:488-494.

Hartweg J, Perera R, Montori V, Dinneen S, Neil HAW, Farmer A. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.:CD003205. DOI: 10.1002/14651858.CD003205.pub2.

Palmer AJ, Dinneen S, Gavin JR III, Gray A, Herman WH, Karter AJ. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. Curr Med Res Opin 2006;22:861-72.

Sarker A, Semple RK, Dinneen SF, O’Rahilly S, Martin SC. Severe hypoalphalipoproteinemia during treatment with rosiglitazone. Diabetes Care 2004;27:2577-80.

Yuyun MF, Dinneen SF, Edwards OM, Wood E, Wareham NJ.  Absolute level and rate of change of albuminuria over 1 year independently predict mortality and cardiovascular events in patients with diabetic nephropathy.  Diabet Med 2003;20:277-282.

Montori VM, Dinneen  SF, Gorman CA, Zimmerman BR, Rizza RA, Bjornsen S, Green EM, Bryant SC, Smith SA, for the Translation Project Investigator Group.  The Impact of Planned Care and a Diabetes Electronic Management System on Community-based Diabetes Care.  The Mayo Health System Diabetes Translation Project.  Diabetes Care 2002;25:1952-1957

Montori VM, Bjornsen SS, Green EM, Drake JM, Bauer C, Bills AR, Dinneen SF, Bryant SC, Smith SA. Validation of a brief self-administered survey to assess patient satisfaction with the delivery of diabetes care in primary care. Am J Manag Care 2002;8:365-372

Halvatsiotis PG, Turk D, Alzaid A, Dinneen S, Rizza RA, Nair KS. Insulin effect on leucine kinetics in type 2 diabetes mellitus. Diabetes Nutr Metab 2002; 15:136-42

Gerstein HC, Mann JFE, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce, Nawaz S, Yusuf S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-426

Farmer A, Montori V, Dinneen S, Clar C.  Fish oil in people with type 2 diabetes mellitus. Cochrane Database Syst Rev. Issue 4, 2001.

Balsiger BM, Kennedy FP, Abu-Lebdeh HS, Collazo-Clavell M, Jensen MD, O’Brien T, Hensrud DD, Dinneen SF, Thompson GB, Que F, Williams DE, Clark MM, Grant JE, Frick MS, Mueller RA, Mai J, Sarr MG. Prospective evaluation of Roux-en-Y gastric bypass as a primary operation for morbid obesity. Mayo Clin Proc 2000;75:673-680.

Dinneen SF, Bjornsen S, Bryant S, Zimmerman B, Gorman C, Rizza R, Smith SA. Towards an optimal model for community-based diabetes care: Design and baseline data from the Mayo Health System Diabetes Translation Project. Journal of Evaluation in Clinical Practice 2000; 6(4):421-429.

Gerstein HC, Mann JFE, Pogue J, Dinneen SF, Halle J-P, Hoogwerf B, Joyce C, Rashkow A, Young J, Zinman B, Yusuf S on behalf of the HOPE study investigators. Prevalence and determinants of microalbuminuria in high-risk diabetic and non-diabetic patients in the heart outcomes prevention evaluation study. Diabetes Care 2000; 23(suppl 2):B35-B39.

Gorman CA, Zimmerman BR, Smith SA, Dinneen SF, Knudsen JB, Holm D, Jorgensen B, Bjornsen S, Planet K, Hanson P, Rizza RA. DEMS-A second generation Diabetes Electronic Management System. Computer methods and programs in biomedicine 2000; 62(2):127-140.

Montori VM, Farmer A, Wollan P, Dinneen SF. Fish oil supplementation in Type 2 Diabetes: A quantitative systematic review. Diabetes Care 2000;23:1407-1415.

Nielsen MF, Dinneen SF, Basu R, Alzaid A, Rizza RA. Failure of nocturnal changes in growth hormone to alter carbohydrate tolerance the following morning. Diabetologia 1998;41:1064-1072.

Dinneen SF, Maldonado D, III, Leibson CI, Klee, GG, Li H, Melton, LJ, III, Rizza RA.  Effects of changing diagnostic criteria on risk of developing diabetes.  Diabetes Care 1998; 21:1408-1413.

Smith SA, Murphy ME, Huschka TR, Dinneen SF, Gorman CA, Zimmerman BR, Rizza RA, Naessens JM.  The impact of a diabetes electronic management system (DEMS) on the care of patients seen in a subspecialty metabolic clinic.  Diabetes Care, 1998; 21(6):972-976.

Frank JW, Camilleri M, Thomforde GM, Dinneen SF, Rizza RA.  Effects of glucagon on postprandial carbohydrate metabolism in nondiabetic humans.  Metabolism 1998; 47(1):7-12.

Nielsen MF, Wise S, Dinneen SF, Schwenk WF, Basu A, Rizza RA.  Assessment of hepatic sensitivity to glucagon in NIDDM:  Use as a tool to estimate the contribution of the indirect pathway to nocturnal glycogen synthesis.  Diabetes 1997; 46:2007-2016.

Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Int Med 1997;157:1413-1418.

Basu A, Alzaid A, Dinneen S, Caumo A, Cobelli C, Rizza RA. Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest 1996; 97(10):2351-2361.

Dinneen S, Alzaid A, Miles J, and Rizza R. Effects of the normal nocturnal rise in cortisol on carbohydrate and fat metabolism in IDDM. Am J Physiol 1995;268:E595-E603.

Dinneen S, Alzaid A, and Rizza RA. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 1995;38:337-343.

Turk D, Alzaid A, Dinneen S, Nair KS, and Rizza R. The effects of non-insulin dependent diabetes mellitus on the kinetics of onset of insulin action in hepatic and extrahepatic tissues. J Clin Invest 1995;95:755-762.

Alzaid AA, Dinneen SF, Turk DJ, Caumo A, Cobelli C, and Rizza RA. Assessment of insulin action and glucose effectiveness in diabetic and nondiabetic humans. J Clin Invest 1994;2341-2348.

Dinneen S, Alzaid A, Miles J, and Rizza R. Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans. J Clin Invest 1993;92(5):2283-2290. 

Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with Type 2 diabetes mellitus. Gastroenterology 1995;109:755-765.

Alzaid AA, Dinneen SF, Moyer TP, and Rizza RA. Effects of insulin on plasma magnesium in NIDDM: evidence for insulin resistance. J Clin Endocrinol Metab 1995;80:1376-1381.

Dinneen SF, Valimaki MJ, Bergstralh EJ, Ebersold JR, Goellner JR, and Hay ID: Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during five decades. J Clin Endocrinol Metab 1995;80:2041-2045.

Review Articles / Editorials:

Dinneen SF. Structured education for people with type 2 diabetes. BMJ 2008;336:459-460

Dinneen SF. Difficult Issues in Current Diabetes Care. In: Brietzke SA, Petit WA Jr, Dinneen SF, editors. Primary care of type 2 diabetes. Wayne (PA): Turner White Communications;2004;(Pt 5):1-13

Dinneen SF. Prevention of cardiovascular disease. In: Brietzke SA, Petit WA Jr, Dinneen SF, editors. Primary care of type 2 diabetes. Wayne (PA): Turner White Communications;2003;1(Pt 3):1–13

Dinneen SF: Management of type 1 diabetes. Medicine. 2001; 30:1:16-22. Updated September 2005.

Book Chapters:

Semple RK, Dinneen SF. An Evidence-Based Approach to Type 2 Diabetes. In: Evidence-Based Endocrinology. Montori V. 2005; The Humana Press Inc.

Dinneen SF, Kinmonth AL.  Diabetes-Type 1 and Type 2. In: Oxford Textbook of Primary Medical Care.  Jones R, Britten N, Culpepper L, Gass DA, Grol R, Mant D, Silagy C. 2003; Oxford University Press.

Montori VM, Dinneen SF.  Currently available oral hypoglycemic agents for Type II diabetes mellitus.  In:  Evidence-Based Diabetes Care.  Gerstein HC, Haynes RB, editors. B.C. Decker Inc. 2001; Chapter 15: p277-294.

Dinneen SF, Rizza RA.  Classification and Diagnosis of Diabetes Mellitus. In:  Endocrinology. Fourth Edition.  DeGroot LJ, Jameson JL, editors. W.B. Saunders 2001; Chapter 53: p756-762. Updated for the Fifth Edition, 2005.

• Disclaimer
• Privacy
• Copyright
• Accessibility